CHICAGO — Repeated intravitreal injections of tocilizumab 4 mg/kg and 8 mg/kg in patients with noninfectious uveitis improved visual acuity and reduced vitreous haze at 6 months, according to a speaker here.
Muhammad Hassan, MD, said intravitreal injections of both tocilizumab doses effectively reduced retinal edema in the STOP-Uveitis study.
“We have also demonstrated injections can also improve posterior segment inflammatory outcomes,” Hassan said at the American Academy of Ophthalmology meeting.
The study included 37 patients with active noninfectious intermediate, posterior
Uncategorized